|
|
|
|
Regd Office :
8-2-293/A/A/ 2, |
|
|
Road No.2, Banjara Hills, Hyderabad 500 033 |
|
|
|
|
|
UNAUDITED
FINANCIAL RESULTS |
|
|
FOR THE QUARTER
ENDED 30th SEPTEMBER, 2007 |
|
|
|
|
|
Rs. Lakhs |
|
|
S No |
Particulars |
3 Months ended
30/09/2007 |
Corresponding 3 months ended in the previous year
30/09/2006 |
Previous
accounting year ended 30/06/2007 |
|
|
Unaudited |
Unaudited |
Unaudited |
|
|
1 |
Net
sales/ Income from operations |
5,003.06 |
4,538.79 |
18,568.64 |
|
|
2 |
Other Income |
8.17 |
7.08 |
234.32 |
|
|
3 |
Total Income (1+2) |
5,011.23 |
4,545.87 |
18,802.96 |
|
|
4 |
Expenditure |
|
|
|
|
|
|
a)
(Increase)/decrease in stock in trade |
(54.11) |
(183.19) |
64.27 |
|
|
|
b) Material
consumption |
2,932.56 |
2,793.77 |
10,678.21 |
|
|
|
c) Manufacturing
expenses |
398.86 |
376.24 |
1,605.24 |
|
|
|
d) Employee cost |
353.15 |
301.24 |
1,156.86 |
|
|
|
e) Administrative
Expenses |
231.59 |
154.69 |
588.40 |
|
|
|
f) Selling & Distibution Expenses |
369.43 |
326.60 |
1,303.43 |
|
|
|
g) Depreciation |
232.47 |
207.88 |
817.73 |
|
|
|
h) Other expenditure |
3.41 |
8.55 |
29.17 |
|
|
|
i) Total |
4,467.36 |
3,985.78 |
16,243.31 |
|
|
5 |
Interest and bank
charges |
268.49 |
309.87 |
1,201.10 |
|
|
6 |
Profit before taxation |
275.38 |
250.22 |
1,358.55 |
|
|
7 |
Current tax expense |
26.14 |
1.85 |
65.26 |
|
|
8 |
Deferred
tax expense |
44.68 |
42.68 |
225.67 |
|
|
9 |
Fringe Benefit
Tax |
2.66 |
2.04 |
8.74 |
|
|
10 |
Net Profit |
201.90 |
203.65 |
1,058.88 |
|
|
11 |
Paid up share capital |
2,004.11 |
1,236.10 |
2,002.36 |
|
|
|
(face value of Rs. 10/- each) |
|
|
|
|
|
12 |
Reserves excluding
Revaluation reserve |
|
|
15,602.15 |
|
|
13 |
Basic
Earnings per share (Rs.)* |
1.01 |
1.65 |
5.29 |
|
|
14 |
Diluted
Earnings per share (Rs.)* |
0.93 |
1.48 |
4.90 |
|
|
15 |
No.
of equity shares |
20,041,134 |
12,360,952 |
20,023,634 |
|
|
16 |
Aggregate
of Public Share holding: |
|
|
|
|
|
|
- Number of shares |
13,688,103 |
6,699,212 |
13,670,603 |
|
|
|
- Percentage of share holding |
68.30% |
54.20% |
68.27% |
|
|
* Not Annualised for
quarter ending |
|
|
|
|
|
|
|
|
|
|
|
NOTES : |
|
|
|
|
1)
The above results have been approved
at the Board Meeting held on 27th October, 2007 and were subjected to |
|
|
limited review by Statutory Auditors. |
|
|
|
|
2) The company has not
received any complaints from investors during the quarter 1st July '07 to
30th Sept '07 |
|
|
and no complaint is pending from
previous quarter. |
|
|
|
3) The company operates
only in the segment of Pharmaceuticals. |
|
|
|
4)
The Share Capital has increased during the year ended 30th June, 2007 on
account of issue of equity to Foreign |
|
|
Body Corporates and Promoters (76,43,062 equity shares of face
value of Rs.10 each). The proceeds of
these |
|
|
issues are mainly being used for setting
up of formulation unit that is under
implementation and is yet to contribute |
|
to the earnings. However, the EPS during the current
quarter/previous year is calculated considering the expanded |
|
Equity
Capital. |
|
|
|
|
5) Diluted EPS includes
16,00,000 share warrants which are yet to be converted. |
|
|
|
6) Figures are regrouped wherever necessary. |
|
|
|
|
for and on behalf of the
Board |
|
|
|
|
|
|
|
|
|
|
|
Place : Hyderabad |
|
Dr.C.Nageswara Rao |
|
|
Date :
27.10.2007 |
|
Chairman |
|
|
|
|
|
|
|
|
|